WO2015011732A3 - Plant poly-phenol and copper (ii) mediated degradation of dna and rna - Google Patents

Plant poly-phenol and copper (ii) mediated degradation of dna and rna Download PDF

Info

Publication number
WO2015011732A3
WO2015011732A3 PCT/IN2014/000491 IN2014000491W WO2015011732A3 WO 2015011732 A3 WO2015011732 A3 WO 2015011732A3 IN 2014000491 W IN2014000491 W IN 2014000491W WO 2015011732 A3 WO2015011732 A3 WO 2015011732A3
Authority
WO
WIPO (PCT)
Prior art keywords
copper
dna
rna
chromatin
fragments
Prior art date
Application number
PCT/IN2014/000491
Other languages
French (fr)
Other versions
WO2015011732A2 (en
Inventor
Indraneel Mittra
Original Assignee
Tata Memorial Centre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tata Memorial Centre filed Critical Tata Memorial Centre
Publication of WO2015011732A2 publication Critical patent/WO2015011732A2/en
Publication of WO2015011732A3 publication Critical patent/WO2015011732A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A composition comprising a plant polyphenol, especially Resveratrol, and copper (II) for the degradation of or preventing or reducing a rise in the level of one or more of circulating fragments of chromatin, DNA and RNA. The molar ratio of plant polyphenol to copper (II) is in the range 1 :1 to 10-10 Higher levels of degradation of chromatin fragments, DNA and RNA occur as the molar ratio of the copper to plant polyphenol to copper (II) is reduced to an optimum level depending on the material to be degraded. The composition provides therapeutic treatment for conditions associated with raised levels of chromatin fragments including cancer and HIV, may enhance cell destruction therapies and, reduce the incidence of death of live cells in the presence of dead cells or fragments of chromatin from dead cells.
PCT/IN2014/000491 2013-07-26 2014-07-25 Plant poly-phenol and copper (ii) mediated degradation of dna and rna WO2015011732A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1528MU2013 IN2013MU01528A (en) 2013-07-26 2013-07-26
IN1528/MUM/2013 2013-07-26

Publications (2)

Publication Number Publication Date
WO2015011732A2 WO2015011732A2 (en) 2015-01-29
WO2015011732A3 true WO2015011732A3 (en) 2015-04-23

Family

ID=51844807

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2014/000491 WO2015011732A2 (en) 2013-07-26 2014-07-25 Plant poly-phenol and copper (ii) mediated degradation of dna and rna

Country Status (2)

Country Link
IN (1) IN2013MU01528A (en)
WO (1) WO2015011732A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3393490A4 (en) * 2015-12-15 2019-11-20 Icahn School of Medicine at Mount Sinai METHODS OF TREATING EXACERBATED INFLAMMATORY RESPONSE WITH TOPOISOMERASE l INHIBITORS
CN115039880A (en) * 2022-07-01 2022-09-13 上海益跬尔生物科技有限公司 Composition for improving metabolic aging and inflammatory aging and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057201A2 (en) * 2002-01-11 2003-07-17 Matthias Rath A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
GB2483121A (en) * 2010-08-27 2012-02-29 Persavita Ltd Composition comprising resveratrol and saffron

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007049286A1 (en) 2005-10-27 2007-05-03 Tata Memorial Centre A system for ex-vivo separation of apoptotic chromatin particles from blood or plasma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057201A2 (en) * 2002-01-11 2003-07-17 Matthias Rath A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
GB2483121A (en) * 2010-08-27 2012-02-29 Persavita Ltd Composition comprising resveratrol and saffron

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AHMAD A ET AL: "Prooxidant activity of resveratrol in the presence of copper ions: Mutagenicity in plasmid DNA", TOXICOLOGY LETTERS, ELSEVIER BIOMEDICAL PRESS, AMSTERDAM, NL, vol. 159, no. 1, 15 October 2005 (2005-10-15), pages 1 - 12, XP027622284, ISSN: 0378-4274, [retrieved on 20051015] *
AZMI A S ET AL: "Resveratrol-Cu(II) induced DNA breakage in human peripheral lymphocytes: Implications for anticancer properties", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 579, no. 14, 6 June 2005 (2005-06-06), pages 3131 - 3135, XP027696360, ISSN: 0014-5793, [retrieved on 20050606] *
FUKUHARA K ET AL: "Resveratrol as a new type of DNA-cleaving agent", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 8, no. 22, 17 November 1998 (1998-11-17), pages 3187 - 3192, XP004143724, ISSN: 0960-894X, DOI: 10.1016/S0960-894X(98)00585-X *
JIN-JIAN LU ET AL: "The short-time treatment with curcumin sufficiently decreases cell viability, induces apoptosis and copper enhances these effects in multidrug-resistant K562/A02 cells", MOLECULAR AND CELLULAR BIOCHEMISTRY, KLUWER ACADEMIC PUBLISHERS, BO, vol. 360, no. 1 - 2, 22 September 2011 (2011-09-22), pages 253 - 260, XP019986322, ISSN: 1573-4919, DOI: 10.1007/S11010-011-1064-2 *
VALAPATUKUTIKADAN DAVIS JOHN ET AL: "Synthesis, characterization and antitumour activities of some synthetic curcuminoid analogues and their copper complexes", TRANSITION METAL CHEMISTRY, KLUWER ACADEMIC PUBLISHERS, DO, vol. 30, no. 2, 1 March 2005 (2005-03-01), pages 229 - 233, XP019269154, ISSN: 1572-901X *
ZHENG L F ET AL: "DNA damage induced by resveratrol and its synthetic analogues in the presence of Cu (II) ions: Mechanism and structure-activity relationship", FREE RADICAL BIOLOGY AND MEDICINE,, vol. 41, no. 12, 15 December 2006 (2006-12-15), pages 1807 - 1816, XP024964209, ISSN: 0891-5849, [retrieved on 20061215], DOI: 10.1016/J.FREERADBIOMED.2006.09.007 *

Also Published As

Publication number Publication date
WO2015011732A2 (en) 2015-01-29
IN2013MU01528A (en) 2015-06-26

Similar Documents

Publication Publication Date Title
MX2017006685A (en) Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies.
MX2021014709A (en) Methods for increasing red blood cell levels and treating sickle-cell disease.
TN2015000353A1 (en) Newcastle disease viruses and uses thereof
MX2014001218A (en) Treatment of breast cancer.
WO2015048345A3 (en) Compositions and formulations for prevention and reduction of tumorigenesis, cancer cell proliferation and invasion, and methods of production and use thereof in cancer treatment
WO2014113429A3 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
WO2015023976A3 (en) Selective grp94 inhibitors and uses thereof
WO2012065121A3 (en) Metabolized conditioned growth medium and methods of use
WO2016200614A3 (en) Bacteria engineered to treat diseases associated with hyperammonemia
EP3271005A4 (en) Synergistic regulated cell death induction with hsp90 inhibitors and nanosecond pulsed electric fields
WO2013134407A3 (en) Procaspase 3 activation by combination therapy
WO2016160621A3 (en) Nk-92 cells in combination therapy with cancer drugs
MX2018000052A (en) Compositions and methods for combination therapy with dengue virus and dendritic cells.
WO2016197024A3 (en) Mir-155 inhibitors for treating cutaneous t cell lymphoma (ctcl)
WO2015200514A3 (en) Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers
PH12014500859A1 (en) Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
EP3638303A4 (en) Compositions and methods for cancer therapy with dengue virus and dendritic cells
MX2021000828A (en) Tumor-selective combination therapy.
WO2016081773A3 (en) Combination cancer therapy with c-met inhibitors and synthetic oligonucleotides
WO2017120204A3 (en) Combination of histone deacetylase inhibitor and immunotherapy
WO2015011732A3 (en) Plant poly-phenol and copper (ii) mediated degradation of dna and rna
PH12017502081B1 (en) Composition, containing quisqualis indica extract, for preventing or treating prostatic hyperplasia
EP3476401A4 (en) Cell death inducer, cell proliferation inhibitor, and pharmaceutical composition for treating disease associated with abnormal cell proliferation
WO2015160719A3 (en) Chitosan shards for biomedical applications
WO2014011624A3 (en) Stabilized multi-functional antioxidant compounds and methods of use

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14792610

Country of ref document: EP

Kind code of ref document: A2